Astrazeneca Plc · LSE:AZN
Astrazeneca — H1 2006 Earnings Presentation
11 slides from Astrazeneca's earnings presentation, Oct 17, 2006
Slide 1: Second Quarter and Half Year Results 2006
Second Quarter and Half Year Results 2006 Cautionary Statement Regarding Forward-Looking Statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This presentation c
Slide 2: Headline results Q2 06
David Brennan Chief Executive Officer Headline results Q2 06 2006 2005 Actual CER $m $m growth growth Sales 6,625 6,132 +8% +10% Operating profit 2,131 1,718 +24% +30% Excl. Divestment gain* +23% EPS $1.02 $0.75 +36% +41% Excl. Divestment gain* $0.97 *Gain from divestment of US anaesthetics and anal
Slide 3: Headline results 1H 06
Headline results 1H 06 2006 2005 Actual CER $m $m growth growth Sales 12,805 11,875 +8% +11% Operating profit* 4,107 3,171 +30% +31% EPS* $1.92 $1.38 +39% +41% Dividends $0. 49 $0.38 +29% Share repurchase $1,627m $1,182m *Excluding $109 m divestment gain operating profit growth was +28% and EPS woul
Slide 4: 1H 2006 sales: Key Growth Drivers
1H 2006 sales: Key Growth Drivers Sales CER $m % growth Nexium® 2,472 +11% Seroquel® 1,656 +29% Crestor® 867 +48% Arimidex® 714 +34% Symbicort® 585 +24% Total 6,294 +23% AstraZeneca Half Year Results 2006 Headline results 1H 06 2006 2005 Actual CER $m $m growth growth Sales 12,805 11,875 +8% +11% No
Slide 5: Steady progress on 2006 priorities
Steady progress on 2006 priorities Maintain business momentum Top line growth 1H06 Sales +11% CER Improved productivity Underlying operating margin (excl. divestment gain, currency) +4.0 percentage points Strong cash generation Interim dividend increased by 29 percent $1.6 billion sh
Slide 6: Q2 2006 sales: Key Growth Drivers
Q2 2006 sales: Key Growth Drivers Sales CER $m % growth Nexium® 1,283 +8% Seroquel® 849 +28% Crestor® 480 +51% Arimidex® 379 +31% Symbicort® 308 +25% Total 3,299 +21% AstraZeneca Half Year Results 2006 Nexium® Q2 Sales: $1,283m +8% US sales affected by Q2 05 1400 Managed Care accrual adjustments 1
Slide 7: PPI Market - TRx EU Growth Trends
PPI Market - TRx EU Growth Trends* Q404 Q105 Q205 Q305 Q405 Q106 Q206 50% 48% 40% TRx EU Growth % 30% 24% 20% 20% 18% 17% 18% 15% 13% 14% 9% 9% 9%9% 10% 8% 6% 10% 5% 7% 5% 3% 2% 4% 1% 0% -1% -2% -4% -4% -5% -10% PPI Omeprazole Other Brands Nexium *TRx Extended Unit growth rates versus same period in
Slide 8: Seroquel and Crestor
Seroquel® Q2 Sales: $849m +28% US TRx +13% YTD 900 Risperdal +2% 800 ROW Zyprexa –15% 700 $229m +24% Rest of World +24% 600 Europe + 20% 500 US Asia Pacific +30% 400 $620m +30% US submission for Seroquel SR™ 300 Seroquel SR filing in EU towards 200 year end 100 US PDUFA date for Bi
Slide 9: Crestor NRx/TRx Volume and TRx Share ex-US
Crestor® NRx/TRx Volume 300,000 250,000 254,108 200,000 Crestor Volume 150,000 100,000 91,419 50,000 0 07/23/04 08/23/04 09/23/04 10/23/04 11/23/04 12/23/04 01/23/05 02/23/05 03/23/05 04/23/05 05/23/05 06/23/05 07/23/05 08/23/05 09/23/05 10/23/05 11/23/05 12/23/05 01/23/06 02/23/06 03/23/06 04/23/06
Slide 10: Arimidex and Symbicort
Arimidex® Q2 Sales: $379m +31% US TRx +26% YTD 400 Market share 36.7% 350 (+2 pts YTD June) 300 ROW New indication in several key $223m +32% EU markets 250 Option to switch after 2-3 200 years of tamoxifen 150 First and only Aromatase US Inhibitor approved for both 100 $156m +28% primary a
Slide 11: Q2 2006 P&L and 2006 FY Outlook
Q2 2006 P&L CER Q2 06 growth Comment Sales $6,625m +10% Gross Profit $5,234m +0.4 pts; Mix/Efficiencies/Merck 79.0% Partially offset by Fx R&D $955m +15% +10% excl Galida charge SG&A $2,290m +5% Other Income $200m Incl $109m divestment gain; royalties Operating Profit $2,131m +30% Underlying +23% (e